Aptinyx Inc.
APTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2023.
Tracking 3 pipeline candidates for Aptinyx Inc..
Run Aptinyx Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aptinyx Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
12.1 months
D/E 1.63
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is Aptinyx Inc.'s lead drug candidate?
Aptinyx Inc.'s most advanced tracked candidate is nyx-2925 (Phase 2) for Chronic pain (specifically painful diabetic peripheral neuropathy and fibromyalgia).
Who is the CEO of Aptinyx Inc.?
Washington Street is the chief executive officer of Aptinyx Inc. (APTX).
What therapeutic areas does Aptinyx Inc. focus on?
Aptinyx Inc. develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.